Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (10097)	11/1/2018 7:07:23 PM
From: tuck	Read Replies (1) \| Respond to of 12215

Speaking of tumor-ass'd antigens, I came across this company, the result of a merge into TapImmune. Claims better than CAR-T results (particularly duration of response) without the cost, the CRS, or the neurotoxicity. Multiple P1s to read out next year. Aims at multiple antigens with T-Cells, not just one. Too good to be true? Some Bellicum people there . . . Marker Therapeutics Corporate Presentation Seems a bit fluffy, but boasts James Allison on the SAB, not that that helped Jounce much. Some decent institutional backers, including a very small stake by the Baker Brothers. $450m MC, don't know how much is cash at this point. Cheers, Tuck